<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://hmg.oxfordjournals.org">
<title>Human Molecular Genetics - recent issues</title>
<link>http://hmg.oxfordjournals.org</link>
<description>Human Molecular Genetics - RSS feed of recent issues (covers the latest 3 issues, including the current issue) </description>
<prism:eIssn>1460-2083</prism:eIssn>
<prism:publicationName>Human Molecular Genetics</prism:publicationName>
<prism:issn>0964-6906</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1349?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1363?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1373?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1386?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1397?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1406?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1418?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1427?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1436?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1446?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1457?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1465?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1482?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1497?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1201?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1214?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1222?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1234?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1245?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1253?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1264?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1278?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1292?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1299?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1306?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1318?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1329?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1336?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1063?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1076?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1087?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1097?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1109?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1120?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1127?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1137?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1147?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1156?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1169?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1175?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1184?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1192?rss=1" />
 </rdf:Seq>
</items>
</channel>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1349?rss=1">
<title><![CDATA[Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/10/1349?rss=1</link>
<description><![CDATA[
<p>Frontotemporal lobar degeneration is a fatal neurodegenerative disease that results in progressive decline in behavior, executive function and sometimes language. Disease mechanisms remain poorly understood. Recently, however, the DNA- and RNA-binding protein TDP-43 has been identified as the major protein present in the hallmark inclusion bodies of frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U), suggesting a role for transcriptional dysregulation in FTLD-U pathophysiology. Using the Affymetrix U133A microarray platform, we profiled global gene expression in both histopathologically affected and unaffected areas of human FTLD-U brains. We then characterized differential gene expression with biological pathway analyses, cluster and principal component analyses, and subgroup analyses based on brain region and progranulin (<I>GRN</I>) gene status. Comparing 17 FTLD-U brains to 11 controls, we identified 414 upregulated and 210 downregulated genes in frontal cortex (<I>P</I>-value &lt; 0.001). Moreover, cluster and principal component analyses revealed that samples with mutations or possibly pathogenic variations in the <I>GRN</I> gene (<I>GRN</I>+, 7/17) had an expression signature that was distinct from both normal controls and FTLD-U samples lacking <I>GRN</I> gene variations (<I>GRN</I>-, 10/17). Within the subgroup of <I>GRN</I>+ FTLD-U, we found &gt;1300 dysregulated genes in frontal cortex (<I>P</I>-value &lt; 0.001), many participating in pathways uniquely dysregulated in the <I>GRN</I>+ cases. Our findings demonstrate a distinct molecular phenotype for <I>GRN</I>+ FTLD-U, not readily apparent on clinical or histopathological examination, suggesting distinct pathophysiological mechanisms for <I>GRN</I>+ and <I>GRN</I>- subtypes of FTLD-U. In addition, these data from a large number of human brains provide a valuable resource for future testing of disease hypotheses.</p>
]]></description>
<dc:creator><![CDATA[Chen-Plotkin, A. S., Geser, F., Plotkin, J. B., Clark, C. M., Kwong, L. K., Yuan, W., Grossman, M., Van Deerlin, V. M., Trojanowski, J. Q., Lee, V. M.-Y.]]></dc:creator>
<dc:date>2008-04-30</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn023</dc:identifier>
<dc:title><![CDATA[Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1362</prism:endingPage>
<prism:publicationDate>2008-05-15</prism:publicationDate>
<prism:startingPage>1349</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1363?rss=1">
<title><![CDATA[Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/10/1363?rss=1</link>
<description><![CDATA[
<p>Retinoblastoma clinical observations revealed the role of tumor suppressor genes in human cancer, Knudson's &lsquo;two-hit&rsquo; model of cancer induction. We now demonstrate that loss of both <I>RB1</I> tumor suppressor gene alleles initiates quiescent <I>RB1</I><sup>&ndash;/&ndash;</sup> retinomas with low level genomic instability and high expression of the senescence-associated proteins p16<sup>INK4a</sup> and p130. Although retinomas can remain unchanged throughout life, highly proliferative, clonal and aneuploid retinoblastomas commonly emerge, exhibiting altered gene copy number and expression of oncogenes (<I>MYCN</I>, <I>E2F3</I>, <I>DEK</I>, <I>KIF14</I> and <I>MDM4</I>) and tumor suppressor genes (<I>CDH11</I>, <I>p75<sup>NTR</sup></I>) and reduced expression of p16<sup>INK4a</sup> and p130. We suggest that <I>RB1</I> inactivation in developing retina induces genomic instability, but senescence can block transformation at the stage of retinoma. However, stable retinoma is rarely clinically observed because progressive genomic instability commonly leads to highly proliferative retinoblastoma.</p>
]]></description>
<dc:creator><![CDATA[Dimaras, H., Khetan, V., Halliday, W., Orlic, M., Prigoda, N. L., Piovesan, B., Marrano, P., Corson, T. W., Eagle, R. C., Squire, J. A., Gallie, B. L.]]></dc:creator>
<dc:date>2008-04-30</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn024</dc:identifier>
<dc:title><![CDATA[Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1372</prism:endingPage>
<prism:publicationDate>2008-05-15</prism:publicationDate>
<prism:startingPage>1363</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1373?rss=1">
<title><![CDATA[Heterodimer formation of wild-type and amyotrophic lateral sclerosis-causing mutant Cu/Zn-superoxide dismutase induces toxicity independent of protein aggregation]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/10/1373?rss=1</link>
<description><![CDATA[
<p>Recent studies provide evidence that wild-type Cu/Zn-superoxide dismutase (SOD1(hWT)) might be an important factor in mutant SOD1-mediated amyotrophic lateral sclerosis (ALS). In order to investigate its functional role in the pathogenesis of ALS, we designed fusion proteins of two SOD1 monomers linked by a polypeptide. We demonstrated that wild-type-like mutants, but not SOD1(G85R) homodimers, as well as mutant heterodimers including SOD1(G85R)-SOD1(hWT) display dismutase activity. Mutant homodimers showed an increased aggregation compared with the corresponding heterodimers in cell cultures and transgenic <I>Caenorhabditis elegans</I>, although SOD1(G85R) heterodimers are more toxic in functional assays. Our data show that (i) toxicity of mutant SOD1 is not correlated to its aggregation potential; (ii) dismutase-inactive mutants form dismutase-active heterodimers with SOD1(hWT); (iii) SOD1(hWT) can be converted to contribute to disease by forming active heterodimers. Therefore, we conclude that toxicity of mutant SOD1 is at least partially mediated through heterodimer formation with SOD1(hWT) <I>in vivo</I> and does not correlate with the aggregation potential of individual mutants.</p>
]]></description>
<dc:creator><![CDATA[Witan, H., Kern, A., Koziollek-Drechsler, I., Wade, R., Behl, C., Clement, A. M.]]></dc:creator>
<dc:date>2008-04-30</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn025</dc:identifier>
<dc:title><![CDATA[Heterodimer formation of wild-type and amyotrophic lateral sclerosis-causing mutant Cu/Zn-superoxide dismutase induces toxicity independent of protein aggregation]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1385</prism:endingPage>
<prism:publicationDate>2008-05-15</prism:publicationDate>
<prism:startingPage>1373</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1386?rss=1">
<title><![CDATA[Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/10/1386?rss=1</link>
<description><![CDATA[
<p>Rett syndrome is an X-linked neurological condition affecting almost exclusively girls that is caused by mutations of the <I>MECP2</I> gene. Recent studies have shown that transgenic delivery of MeCP2 function to <I>Mecp2</I>-deficient male mice can improve their Rett-like behavior. However, as the brain of a Rett girl contains a mosaic of MeCP2 expressing and non-expressing neurons, and the over-expression of MeCP2 in neurons can induce a severe progressive neurological phenotype, testing whether functional rescue can be achieved by gene re-introduction strategies in a female model of Rett syndrome is warranted. To address this, we generated transgenic mice expressing an epitope-tagged <I>Mecp2</I> transgene in forebrain neurons. These mice over-express MeCP2 protein at about 1.6 times normal levels in cortex and develop impaired motor behavior by 9&ndash;12 months of age. To test whether forebrain-targeted MeCP2 restoration would improve behavior in female <I>Mecp2</I><sup>&ndash;/+</sup> mice, we crossed these transgenics with <I>Mecp2</I><sup>&ndash;/+</sup> mice and examined the behavioral properties of the female rescue mice for 1 year. These assessments revealed that the diminished rearing activity, impaired mobility and the diminished locomotive activity of female <I>Mecp2</I><sup>&ndash;/+</sup> mice were restored to wild-type levels in the rescue mice. These results show that improvement of Rett-like behavior can be achieved in <I>Mecp2</I><sup>&ndash;/+</sup> females by targeted gene re-introduction without inducing deficits relating to MeCP2 over-expression.</p>
]]></description>
<dc:creator><![CDATA[Jugloff, D. G.M., Vandamme, K., Logan, R., Visanji, N. P., Brotchie, J. M., Eubanks, J. H.]]></dc:creator>
<dc:date>2008-04-30</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn026</dc:identifier>
<dc:title><![CDATA[Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1396</prism:endingPage>
<prism:publicationDate>2008-05-15</prism:publicationDate>
<prism:startingPage>1386</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1397?rss=1">
<title><![CDATA[A loss-of-function mutation in the binding domain of HAND1 predicts hypoplasia of the human hearts]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/10/1397?rss=1</link>
<description><![CDATA[
<p>Hypoplasia of the human heart is the most severe form of congenital heart disease (CHD) and usually lethal during early infancy. It is a leading cause of neonatal loss, especially in infants diagnosed with hypoplastic left heart syndrome (HLHS), a condition where the left side of the heart including the aorta, aortic valve, left ventricle (LV) and mitral valve are underdeveloped. The molecular causes of HLHS are unclear, but the basic helix&ndash;loop&ndash;helix (bHLH) transcription factor heart and neural crest derivatives expressed 1 (Hand1), may be a candidate culprit for this condition. The absence of Hand1 in mice resulted in the failure of rightward looping of the heart tube, a severely hypoplastic LV and outflow tract abnormalities. Nonetheless, no <I>HAND1</I> mutations associated with human CHD have been reported so far. We sequenced the human <I>HAND1</I> gene in heart tissues derived from 31 unrelated patients diagnosed with hypoplastic hearts. We detected in 24 of 31 hypoplastic ventricles, a common frameshift mutation (A126fs) in the bHLH domain, which is necessary for DNA binding and combinatorial interactions. The resulting mutant protein, unlike wild-type (wt) HAND1, was unable to modulate transcription of reporter constructs containing specific DNA-binding sites. Thus, in hypoplastic human hearts HAND1 function is impaired.</p>
]]></description>
<dc:creator><![CDATA[Reamon-Buettner, S. M., Ciribilli, Y., Inga, A., Borlak, J.]]></dc:creator>
<dc:date>2008-04-30</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn027</dc:identifier>
<dc:title><![CDATA[A loss-of-function mutation in the binding domain of HAND1 predicts hypoplasia of the human hearts]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1405</prism:endingPage>
<prism:publicationDate>2008-05-15</prism:publicationDate>
<prism:startingPage>1397</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1406?rss=1">
<title><![CDATA[Deficiency of the INCL protein Ppt1 results in changes in ectopic F1-ATP synthase and altered cholesterol metabolism]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/10/1406?rss=1</link>
<description><![CDATA[
<p>Infantile neuronal ceroid lipofuscinosis (INCL) is a severe neurodegenerative disease caused by deficiency of palmitoyl protein thioesterase 1 (PPT1). INCL results in dramatic loss of thalamocortical neurons, but the disease mechanism has remained elusive. In the present work we describe the first interaction partner of PPT1, the F<SUB>1</SUB>-complex of the mitochondrial ATP synthase, by co-purification and <I>in vitro</I>-binding assays. In addition to mitochondria, subunits of F<SUB>1</SUB>-complex have been reported to localize in the plasma membrane, and to be capable of acting as receptors for various ligands such as apolipoprotein A-1. We verified here the plasma membrane localization of F<SUB>1</SUB>-subunits on mouse primary neurons and fibroblasts by cell surface biotinylation and TIRF-microscopy. To gain further insight into the Ppt1-mediated properties of the F<SUB>1</SUB>-complex, we utilized the Ppt1-deficient <I>Ppt1<sup>ex4</sup></I> mice. While no changes in the mitochondrial function could be detected in the brain of the <I>Ppt1<sup>ex4</sup></I> mice, the levels of F<SUB>1</SUB>-subunits  and &beta; on the plasma membrane were specifically increased in the <I>Ppt1<sup>ex4</sup></I> neurons. Significant changes were also detected in the apolipoprotein A-I uptake by the <I>Ppt1<sup>ex4</sup></I> neurons and the serum lipid composition in the <I>Ppt1<sup>ex4</sup></I> mice. These data indicate neuron-specific changes for F<SUB>1</SUB>-complex in the Ppt1-deficient cells and give clues for a possible link between lipid metabolism and neurodegeneration in INCL.</p>
]]></description>
<dc:creator><![CDATA[Lyly, A., Marjavaara, S. K., Kyttala, A., Uusi-Rauva, K., Luiro, K., Kopra, O., Martinez, L. O., Tanhuanpaa, K., Kalkkinen, N., Suomalainen, A., Jauhiainen, M., Jalanko, A.]]></dc:creator>
<dc:date>2008-04-30</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn028</dc:identifier>
<dc:title><![CDATA[Deficiency of the INCL protein Ppt1 results in changes in ectopic F1-ATP synthase and altered cholesterol metabolism]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1417</prism:endingPage>
<prism:publicationDate>2008-05-15</prism:publicationDate>
<prism:startingPage>1406</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1418?rss=1">
<title><![CDATA[Age-associated mosaic respiratory chain deficiency causes trans-neuronal degeneration]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/10/1418?rss=1</link>
<description><![CDATA[
<p>Heteroplasmic mitochondrial DNA (mtDNA) mutations (mutations present only in a subset of cellular mtDNA copies) arise <I>de novo</I> during the normal ageing process or may be maternally inherited in pedigrees with mitochondrial disease syndromes. A pathogenic mtDNA mutation causes respiratory chain deficiency only if the fraction of mutated mtDNA exceeds a certain threshold level. These mutations often undergo apparently random mitotic segregation and the levels of normal and mutated mtDNA can vary considerably between cells of the same tissue. In human ageing, segregation of somatic mtDNA mutations leads to mosaic respiratory chain deficiency in a variety of tissues, such as brain, heart and skeletal muscle. A similar pattern of mutation segregation with mosaic respiratory chain deficiency is seen in patients with mitochondrial disease syndromes caused by inherited pathogenic mtDNA mutations. We have experimentally addressed the role of mosaic respiratory chain deficiency in ageing and mitochondrial disease by creating mouse chimeras with a mixture of normal and respiratory chain-deficient neurons in cerebral cortex. We report here that a low proportion (&gt;20%) of respiratory chain-deficient neurons in the forebrain are sufficient to cause symptoms, whereas premature death of the animal occurs only if the proportion is high (&gt;60&ndash;80%). The presence of neurons with normal respiratory chain function does not only prevent mortality but also delays the age at which onset of disease symptoms occur. Unexpectedly, respiratory chain-deficient neurons have adverse effect on normal adjacent neurons and induce <I>trans</I>-neuronal degeneration. In summary, our study defines the minimal threshold level of respiratory chain-deficient neurons needed to cause symptoms and also demonstrate that neurons with normal respiratory chain function ameliorate disease progression. Finally, we show that respiratory chain-deficient neurons induce death of normal neurons by a <I>trans</I>-neuronal degeneration mechanism. These findings provide novel insights into the pathogenesis of mosaic respiratory chain deficiency in ageing and mitochondrial disease.</p>
]]></description>
<dc:creator><![CDATA[Dufour, E., Terzioglu, M., Sterky, F. H., Sorensen, L., Galter, D., Olson, L., Wilbertz, J., Larsson, N.-G.]]></dc:creator>
<dc:date>2008-04-30</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn030</dc:identifier>
<dc:title><![CDATA[Age-associated mosaic respiratory chain deficiency causes trans-neuronal degeneration]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1426</prism:endingPage>
<prism:publicationDate>2008-05-15</prism:publicationDate>
<prism:startingPage>1418</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1427?rss=1">
<title><![CDATA[Different mechanisms cause imprinting defects at the IGF2/H19 locus in Beckwith-Wiedemann syndrome and Wilms' tumour]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/10/1427?rss=1</link>
<description><![CDATA[
<p>The parent of origin-dependent expression of the <I>IGF2</I> and <I>H19</I> genes is controlled by the imprinting centre 1 (IC1) consisting in a methylation-sensitive chromatin insulator. Deletions removing part of IC1 have been found in patients affected by the overgrowth- and tumour-associated Beckwith&ndash;Wiedemann syndrome (BWS). These mutations result in the hypermethylation of the remaining IC1 region, loss of <I>IGF2/H19</I> imprinting and fully penetrant BWS phenotype when maternally transmitted. We now report that 12 additional cases with IC1 hypermethylation have a similar clinical phenotype but showed neither a detectable deletion nor other mutation in the local vicinity. Likewise, no IC1 deletion was detected in 40 sporadic non-syndromic Wilms' tumours. A detailed analysis of the BWS patients showed that the hypermethylation variably affected the IC1 region and was generally mosaic. We observed that all these cases were sporadic and in at least two families affected and unaffected members shared the same maternal IC1 allele but not the abnormal maternal chromosome epigenotype. Furthermore, the chromosome with the imprinting defect derived from either the maternal grandfather or maternal grandmother. Overall, these results indicate that methylation-imprinting defects at the <I>IGF2&ndash;H19</I> locus can result from inherited mutations of the IC and have high recurrence risk or arise independently from the sequence context and generally not transmitted to the progeny. Despite these differences, the epigenetic abnormalities are usually present in the patients in the mosaic form and probably acquired by post-zygotic <I>de novo</I> methylation. Distinguishing between these two groups of cases is important for genetic counselling.</p>
]]></description>
<dc:creator><![CDATA[Cerrato, F., Sparago, A., Verde, G., De Crescenzo, A., Citro, V., Cubellis, M. V., Rinaldi, M. M., Boccuto, L., Neri, G., Magnani, C., D'Angelo, P., Collini, P., Perotti, D., Sebastio, G., Maher, E. R., Riccio, A.]]></dc:creator>
<dc:date>2008-04-30</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn031</dc:identifier>
<dc:title><![CDATA[Different mechanisms cause imprinting defects at the IGF2/H19 locus in Beckwith-Wiedemann syndrome and Wilms' tumour]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1435</prism:endingPage>
<prism:publicationDate>2008-05-15</prism:publicationDate>
<prism:startingPage>1427</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1436?rss=1">
<title><![CDATA[siRNA knock-down of mutant torsinA restores processing through secretory pathway in DYT1 dystonia cells]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/10/1436?rss=1</link>
<description><![CDATA[
<p>Most cases of the dominantly inherited movement disorder, early onset torsion dystonia (DYT1) are caused by a mutant form of torsinA lacking a glutamic acid residue in the C-terminal region (torsinAE). TorsinA is an AAA+ protein located predominantly in the lumen of the endoplasmic reticulum (ER) and nuclear envelope apparently involved in membrane structure/movement and processing of proteins through the secretory pathway. A reporter protein <I>Gaussia</I> luciferase (Gluc) shows a reduced rate of secretion in primary fibroblasts from DYT1 patients expressing endogenous levels of torsinA and torsinAE when compared with control fibroblasts expressing only torsinA. In this study, small interfering RNA (siRNA) oligonucleotides were identified, which downregulate the levels of torsinA or torsinAE mRNA and protein by over 65% following transfection. Transfection of siRNA for torsinA message in control fibroblasts expressing Gluc reduced levels of luciferase secretion compared with the same cells non-transfected or transfected with a non-specific siRNA. Transfection of siRNA selectively inhibiting torsinAE message in DYT fibroblasts increased luciferase secretion when compared with cells non-transfected or transfected with a non-specific siRNA. Further, transduction of DYT1 cells with a lentivirus vector expressing torsinA, but not torsinB, also increased secretion. These studies are consistent with a role for torsinA as an ER chaperone affecting processing of proteins through the secretory pathway and indicate that torsinAE acts to inhibit this torsinA activity. The ability of allele-specific siRNA for torsinAE to normalize secretory function in DYT1 patient cells supports its potential role as a therapeutic agent in early onset torsion dystonia.</p>
]]></description>
<dc:creator><![CDATA[Hewett, J. W., Nery, F. C., Niland, B., Ge, P., Tan, P., Hadwiger, P., Tannous, B. A., Sah, D. W.Y., Breakefield, X. O.]]></dc:creator>
<dc:date>2008-04-30</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn032</dc:identifier>
<dc:title><![CDATA[siRNA knock-down of mutant torsinA restores processing through secretory pathway in DYT1 dystonia cells]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1445</prism:endingPage>
<prism:publicationDate>2008-05-15</prism:publicationDate>
<prism:startingPage>1436</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1446?rss=1">
<title><![CDATA[Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/10/1446?rss=1</link>
<description><![CDATA[
<p>In neurodegenerative disorders associated with primary or secondary mitochondrial defects such as Huntington's disease (HD), cells of the striatum are particularly vulnerable to cell death, although the mechanisms by which this cell death is induced are unclear. Dopamine, found in high concentrations in the striatum, may play a role in striatal cell death. We show that in primary striatal cultures, dopamine increases the toxicity of an N-terminal fragment of mutated huntingtin (Htt-171-82Q). Mitochondrial complex II protein (mCII) levels are reduced in HD striatum, indicating that this protein may be important for dopamine-mediated striatal cell death. We found that dopamine enhances the toxicity of the selective mCII inhibitor, 3-nitropropionic acid. We also demonstrated that dopamine doses that are insufficient to produce cell loss regulate mCII expression at the mRNA, protein and catalytic activity level. We also show that dopamine-induced down-regulation of mCII levels can be blocked by several dopamine D2 receptor antagonists. Sustained overexpression of mCII subunits using lentiviral vectors abrogated the effects of dopamine, both by high dopamine concentrations alone and neuronal death induced by low dopamine concentrations together with Htt-171-82Q. This novel pathway links dopamine signaling and regulation of mCII activity and could play a key role in oxidative energy metabolism and explain the vulnerability of the striatum in neurodegenerative diseases.</p>
]]></description>
<dc:creator><![CDATA[Benchoua, A., Trioulier, Y., Diguet, E., Malgorn, C., Gaillard, M.-C., Dufour, N., Elalouf, J.-M., Krajewski, S., Hantraye, P., Deglon, N., Brouillet, E.]]></dc:creator>
<dc:date>2008-04-30</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn033</dc:identifier>
<dc:title><![CDATA[Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1456</prism:endingPage>
<prism:publicationDate>2008-05-15</prism:publicationDate>
<prism:startingPage>1446</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1457?rss=1">
<title><![CDATA[Identification of genetic variants that influence circulating IGF1 levels: a targeted search strategy]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/10/1457?rss=1</link>
<description><![CDATA[
<p>An important class of genetic variants that affect disease susceptibility may lie within regulatory elements that influence gene expression. Regulatory sequences are difficult to identify and may be distant from the genes they regulate, but many lie within evolutionarily conserved regions (ECRs). We used comparative genomics to identify 12 ECRs up to 75 kb 5' to and within introns of <I>IGF1</I>. These were screened by high-resolution melting curve analysis, and 18 single-nucleotide polymorphisms (SNPs) were identified, including five novel variants. We analysed two large population-based series of healthy women to test the nine SNPs with minor allele frequency (MAF) &gt;1% within ECRs. Three of the nine SNPs within ECRs (rs35455143, rs35765817 and rs3839984) were significantly associated with circulating IGF1 levels in a multivariate analysis (<I>P</I> &le; 0.02 for each SNP, overall significance <I>P</I> &lt; 0.001). All three are uncommon SNPs (MAF &le; 10%) that lie &gt;70 kb 5' of <I>IGF1</I>. Two (rs35455143 and rs35765817) are in strong LD with each other and appear to have opposite effects on circulating IGF1. Our results on a subset of other SNPs in or near <I>IGF1</I> were consistent with previously reported associations with IGF1 levels, although only one (rs35767: <I>P</I> = 0.05) was statistically significant. We believe that this is the first systematic study of an association between a phenotype and SNPs within ECRs extending over a large region adjacent to a gene. Targeting ECRs appears to be a useful strategy for identifying a subset of potentially functional non-coding regulatory SNPs.</p>
]]></description>
<dc:creator><![CDATA[Palles, C., Johnson, N., Coupland, B., Taylor, C., Carvajal, J., Holly, J., Fentiman, I. S., dos Santos Silva, I., Ashworth, A., Peto, J., Fletcher, O.]]></dc:creator>
<dc:date>2008-04-30</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn034</dc:identifier>
<dc:title><![CDATA[Identification of genetic variants that influence circulating IGF1 levels: a targeted search strategy]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1464</prism:endingPage>
<prism:publicationDate>2008-05-15</prism:publicationDate>
<prism:startingPage>1457</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1465?rss=1">
<title><![CDATA[Insulin receptor and lipid metabolism pathology in ataxin-2 knock-out mice]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/10/1465?rss=1</link>
<description><![CDATA[
<p>Ataxin-2 is a cytoplasmic protein, product of the <I>SCA2</I> gene. Expansion of the normal polyglutamine tract in the protein leads to the neurodegenerative disorder Spino-Cerebellar Ataxia type 2 (SCA2). Although ataxin-2 has been related to polyribosomes, endocytosis and actin-cytoskeleton organization, its biological function remains unknown. In the present study, an ataxin-2 deficient mouse (<I>Sca2</I><sup>&ndash;/&ndash;</sup>) was generated to investigate the functional role of this protein. Homozygous mice exhibited reduced fertility and locomotor hyperactivity. In analyses up to the age of 6 months, the absence of ataxin-2 led to abdominal obesity and hepatosteatosis. This was associated with reduced insulin receptor expression in liver and cerebellum, although the mRNA levels were increased indicating a post-transcriptional effect of ataxin-2 on the insulin receptor status. As in insulin resistance syndromes, insulin levels were increased in pancreas and blood serum. In the cerebellum, increased levels of gangliosides and sulfatides, as well as decreased cholesterol dynamics, may be relevant for cellular membrane functions, and alterations in the sphingomyelin cycle may affect second messengers. Thus, the data suggest altered signaling in ataxin-2 deficient organisms.</p>
]]></description>
<dc:creator><![CDATA[Lastres-Becker, I., Brodesser, S., Lutjohann, D., Azizov, M., Buchmann, J., Hintermann, E., Sandhoff, K., Schurmann, A., Nowock, J., Auburger, G.]]></dc:creator>
<dc:date>2008-04-30</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn035</dc:identifier>
<dc:title><![CDATA[Insulin receptor and lipid metabolism pathology in ataxin-2 knock-out mice]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1481</prism:endingPage>
<prism:publicationDate>2008-05-15</prism:publicationDate>
<prism:startingPage>1465</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1482?rss=1">
<title><![CDATA[Aberrant molecular properties shared by familial Parkinson's disease-associated mutant UCH-L1 and carbonyl-modified UCH-L1]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/10/1482?rss=1</link>
<description><![CDATA[
<p>Parkinson&rsquo;s disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons. The I93M mutation in ubiquitin C-terminal hydrolase L1 (UCH-L1) is associated with familial PD, and we have previously shown that the I93M UCH-L1-transgenic mice exhibit dopaminergic cell loss. Over 90% of neurodegenerative diseases, including PD, occur sporadically. However, the molecular mechanisms underlying sporadic PD as well as PD associated with I93M UCH-L1 are largely unknown. UCH-L1 is abundant (1&ndash;5% of total soluble protein) in the brain and is a major target of oxidative/carbonyl damage associated with sporadic PD. As well, abnormal microtubule dynamics and tubulin polymerization are associated with several neurodegenerative diseases including frontotemporal dementia and parkinsonism linked to chromosome 17. Here we show that familial PD-associated mutant UCH-L1 and carbonyl-modified UCH-L1 display shared aberrant properties: compared with wild-type UCH-L1, they exhibit increased insolubility and elevated interactions with multiple proteins, which are characteristics of several neurodegenerative diseases-linked mutants. Circular dichroism analyses suggest similar structural changes in both UCH-L1 variants. We further report that one of the proteins interacting with UCH-L1 is tubulin, and that aberrant interaction of mutant or carbonyl-modified UCH-L1 with tubulin modulates tubulin polymerization. These findings may underlie the toxic gain of function by mutant UCH-L1 in familial PD. Our results also suggest that the carbonyl modification of UCH-L1 and subsequent abnormal interactions of carbonyl-modified UCH-L1 with multiple proteins, including tubulin, constitute one of the causes of sporadic PD.</p>
]]></description>
<dc:creator><![CDATA[Kabuta, T., Setsuie, R., Mitsui, T., Kinugawa, A., Sakurai, M., Aoki, S., Uchida, K., Wada, K.]]></dc:creator>
<dc:date>2008-04-30</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn037</dc:identifier>
<dc:title><![CDATA[Aberrant molecular properties shared by familial Parkinson's disease-associated mutant UCH-L1 and carbonyl-modified UCH-L1]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1496</prism:endingPage>
<prism:publicationDate>2008-05-15</prism:publicationDate>
<prism:startingPage>1482</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/10/1497?rss=1">
<title><![CDATA[A meta-analysis of European and Asian cohorts reveals a global role of a functional SNP in the 5' UTR of GDF5 with osteoarthritis susceptibility]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/10/1497?rss=1</link>
<description><![CDATA[
<p>We have performed a meta-analysis combining data for more than 11 000 individuals. It provides compelling evidence for a positive association between a functional single-nucleotide polymorphism (SNP) in the 5'-UTR of <I>GDF5</I> (+104T/C; rs143383) and osteoarthritis (OA) in European and Asian populations. This SNP has recently been reported to be associated with OA in Japanese and Han Chinese populations. Attempts to replicate this association in European samples have been inconclusive, as no association was found in the case&ndash;control cohorts from the UK, Spain and Greece when studied individually. However, the pooled data of UK and Spain found an association of the T-allele with an odds ratio (OR) of 1.10. Although the European studies had adequate power to replicate the original findings from the Japanese cohort (OR = 1.79), these results suggest that the role of the <I>GDF5</I> polymorphism may not be as strong in Europeans. To clarify whether the European studies were hampered by insufficient power, we combined new data from the UK and the Netherlands with the three published studies of Europe and Asia. The results provide strong evidence of a positive association of the <I>GDF5</I> SNP with knee OA for Europeans as well as for Asians. The combined association for both ethnic groups is highly significant for the allele frequency model (<I>P</I> = 0.0004, OR = 1.21) and the dominant model (<I>P</I> &lt; 0.0001, OR = 1.48). These findings represent the first highly significant evidence for a risk factor for the development of OA which affects two highly diverse ethnic groups.</p>
]]></description>
<dc:creator><![CDATA[Chapman, K., Takahashi, A., Meulenbelt, I., Watson, C., Rodriguez-Lopez, J., Egli, R., Tsezou, A., Malizos, K. N., Kloppenburg, M., Shi, D., Southam, L., van der Breggen, R., Donn, R., Qin, J., Doherty, M., Slagboom, P. E., Wallis, G., Kamatani, N., Jiang, Q., Gonzalez, A., Loughlin, J., Ikegawa, S.]]></dc:creator>
<dc:date>2008-04-30</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn038</dc:identifier>
<dc:title><![CDATA[A meta-analysis of European and Asian cohorts reveals a global role of a functional SNP in the 5' UTR of GDF5 with osteoarthritis susceptibility]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>10</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1504</prism:endingPage>
<prism:publicationDate>2008-05-15</prism:publicationDate>
<prism:startingPage>1497</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1201?rss=1">
<title><![CDATA[A common disease-associated missense mutation in alpha-sarcoglycan fails to cause muscular dystrophy in mice]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/9/1201?rss=1</link>
<description><![CDATA[
<p>Limb-girdle muscular dystrophy type 2D (LGMD2D) is caused by autosomal recessive mutations in the -sarcoglycan gene. An R77C substitution is the most prevalent cause of the disease, leading to disruption of the sarcoglycan&ndash;sarcospan complex. To model this common mutation, we generated knock-in mice with an H77C substitution in -sarcoglycan. The floxed neomycin (Neo)-cassette retained at the targeted <I>H77C -sarcoglycan</I> locus caused a loss of -sarcoglycan expression, resulting in muscular dystrophy in homozygotes, whereas Cre-mediated deletion of the floxed Neo-cassette led to recovered H77C -sarcoglycan expression. Contrary to expectations, mice homozygous for the H77C-encoding allele expressed both this mutant -sarcoglycan and the other components of the sarcoglycan&ndash;sarcospan complex in striated muscle, and did not develop muscular dystrophy. Accordingly, conditional rescued expression of the H77C protein in striated muscle of the -sarcoglycan-deficient mice prevented the disease. Adding to the case that the behavior of mutant -sarcoglycan is different between humans and mice, mutant human R77C -sarcoglycan restored the expression of the sarcoglycan&ndash;sarcospan complex when introduced by adenoviral vector into the skeletal muscle of previously created <I>-sarcoglycan</I> null mice. These findings indicate that the -sarcoglycan with the most frequent missense mutation in LGMD2D is correctly processed, is transported to the sarcolemma, and is fully functional in mouse muscle. Our study presents an unexpected difference in the behavior of a missense-mutated protein in mice versus human patients, and emphasizes the need to understand species-specific protein quality control systems.</p>
]]></description>
<dc:creator><![CDATA[Kobuke, K., Piccolo, F., Garringer, K. W., Moore, S. A., Sweezer, E., Yang, B., Campbell, K. P.]]></dc:creator>
<dc:date>2008-04-17</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn009</dc:identifier>
<dc:title><![CDATA[A common disease-associated missense mutation in alpha-sarcoglycan fails to cause muscular dystrophy in mice]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>9</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1213</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>1201</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1214?rss=1">
<title><![CDATA[Mannosidase I inhibition rescues the human {alpha}-sarcoglycan R77C recurrent mutation]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/9/1214?rss=1</link>
<description><![CDATA[
<p>Limb girdle muscular dystrophy type 2D (LGMD2D, OMIM600119) is a genetic progressive myopathy that is caused by mutations in the human -sarcoglycan gene (<I>SGCA</I>). Here, we have introduced in mice the most prevalent LGMD2D mutation, R77C. It should be noted that the natural murine residue at this position is a histidine. The model is, therefore, referred as <I>Sgca</I><sup>H77C/H77C</sup>. Unexpectedly, we observed an absence of LGMD2D-like phenotype at histological or physiological level. Using a heterologous cellular model of the sarcoglycan complex formation, we showed that the R77C allele encodes a protein that fails to be delivered to its proper cellular localization in the plasma membrane, and consequently to the disappearance of a positively charged residue. Subsequently, we transferred an AAV vector coding for the human R77C protein in the muscle of <I>Sgca</I>-null mice and were able to pharmacologically rescue the R77C protein from endoplasmic reticulum-retention using proteasome or mannosidase I inhibitors. This suggests a therapeutic approach for LGMD2D patients carrying mutations that impair -sarcoglycan trafficking.</p>
]]></description>
<dc:creator><![CDATA[Bartoli, M., Gicquel, E., Barrault, L., Soheili, T., Malissen, M., Malissen, B., Vincent-Lacaze, N., Perez, N., Udd, B., Danos, O., Richard, I.]]></dc:creator>
<dc:date>2008-04-17</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn029</dc:identifier>
<dc:title><![CDATA[Mannosidase I inhibition rescues the human {alpha}-sarcoglycan R77C recurrent mutation]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>9</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1221</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>1214</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1222?rss=1">
<title><![CDATA[Brachydactyly type A2 associated with a defect in proGDF5 processing]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/9/1222?rss=1</link>
<description><![CDATA[
<p>We investigated a family with a brachydactyly type A2 and identified a heterozygous arginine to glutamine (R380Q) substitution in the growth/differentiation factor 5 (GDF5) in all affected individuals. The observed mutation is located at the processing site of the protein, at which the GDF5 precursor is thought to be cleaved releasing the mature molecule from the prodomain. In order to test the effect of the mutation, we generated the GDF5-R380Q mutant and a cleavage-resistant proGDF5 mutant (R380A/R381A) <I>in vitro</I>. Both mutants were secreted from chicken micromass cultures, but showed diminished biological activity. Western blot analyses showed that wt GDF5 was processed by the chicken micromass cells, whereas the mutants were not, indicating that the mutations interfere with processing and that this leads to a strong reduction of biological activity. To test the requirements for GDF5 processing <I>in vitro</I> we produced recombinant human (rh) proGDF5 wild-type protein in <I>Escherichia coli</I>. The results show that unprocessed (rh) proGDF5 is virtually inactive but can be proteolytically activated by different enzymes such as trypsin, furin, and MMP3. (rh) proGDF5 could thus be used as a locally administered depot form with retarded release of activity. In contrast to mature rhGDF5, (rh) proGDF5 shows a high solubility at physiological pH, a characteristic that might be useful for therapeutic applications.</p>
]]></description>
<dc:creator><![CDATA[Ploger, F., Seemann, P., Schmidt-von Kegler, M., Lehmann, K., Seidel, J., Kjaer, K. W., Pohl, J., Mundlos, S.]]></dc:creator>
<dc:date>2008-04-17</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn012</dc:identifier>
<dc:title><![CDATA[Brachydactyly type A2 associated with a defect in proGDF5 processing]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>9</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1233</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>1222</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1234?rss=1">
<title><![CDATA[Association of NTRK3 and its interaction with NGF suggest an altered cross-regulation of the neurotrophin signaling pathway in eating disorders]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/9/1234?rss=1</link>
<description><![CDATA[
<p>Eating disorders (EDs) are complex psychiatric diseases that include anorexia nervosa and bulimia nervosa, and have higher than 50% heritability. Previous studies have found association of BDNF and NTRK2 to ED, while animal models suggest that other neurotrophin genes might also be involved in eating behavior. We have performed a family-based association study with 151 TagSNPs covering 10 neurotrophin signaling genes: <I>NGFB, BDNF, NTRK1, NGFR/p75, NTF4/5, NTRK2, NTF3, NTRK3, CNTF</I> and <I>CNTFR</I> in 371 ED trios of Spanish, French and German origin. Besides several nominal associations, we found a strong significant association after correcting for multiple testing (<I>P</I> = 1.04 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;4</sup>) between ED and rs7180942, located in the <I>NTRK3</I> gene, which followed an overdominant model of inheritance. Interestingly, HapMap unrelated individuals carrying the rs7180942 risk genotypes for ED showed higher levels of expression of <I>NTRK3</I> in lymphoblastoid cell lines. Furthermore, higher expression of the orthologous murine <I>Ntrk3</I> gene was also detected in the hypothalamus of the <I>anx/anx</I> mouse model of anorexia. Finally, variants in NGFB gene appear to modify the risk conferred by the NTRK3 rs7180942 risk genotypes (<I>P</I> = 4.0 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;5</sup>) showing a synergistic epistatic interaction. The reported data, in addition to the previous reported findings for BDNF and NTRK2, point neurotrophin signaling genes as key regulators of eating behavior and their altered cross-regulation as susceptibility factors for EDs.</p>
]]></description>
<dc:creator><![CDATA[Mercader, J. M., Saus, E., Aguera, Z., Bayes, M., Boni, C., Carreras, A., Cellini, E., de Cid, R., Dierssen, M., Escaramis, G., Fernandez-Aranda, F., Forcano, L., Gallego, X., Gonzalez, J. R., Gorwood, P., Hebebrand, J., Hinney, A., Nacmias, B., Puig, A., Ribases, M., Ricca, V., Romo, L., Sorbi, S., Versini, A., Gratacos, M., Estivill, X.]]></dc:creator>
<dc:date>2008-04-17</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn013</dc:identifier>
<dc:title><![CDATA[Association of NTRK3 and its interaction with NGF suggest an altered cross-regulation of the neurotrophin signaling pathway in eating disorders]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>9</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1244</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>1234</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1245?rss=1">
<title><![CDATA[Effect of spastic paraplegia mutations in KIF5A kinesin on transport activity]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/9/1245?rss=1</link>
<description><![CDATA[
<p>Hereditary spastic paraplegia (HSP) is a neurodegenerative disease caused by motoneuron degeneration. It is linked to at least 30 loci, among them SPG10, which causes dominant forms and originates in point mutations in the neuronal Kinesin-1 gene (KIF5A). Here, we investigate the motility of KIF5A and four HSP mutants. All mutations are single amino-acid exchanges and located in kinesin's motor or neck domain. The mutation in the neck (A361V) did not change the gliding properties <I>in vitro</I>, the others either reduced microtubule affinity or gliding velocity or both. In laser-trapping assays, none of the mutants moved more than a few steps along microtubules. Motility assays with mixtures of homodimeric wild-type, homodimeric mutant and heterodimeric wild-type/mutant motors revealed that only one mutant (N256S) reduces the gliding velocity at ratios present in heterozygous patients, whereas the others (K253N, R280C) do not. Attached to quantum dots as artificial cargo, mixtures involving N256S mutants produced slower cargo populations lagging behind in transport, whereas mixtures with the other mutants led to populations of quantum dots that rarely bound to microtubules. These differences indicate that the dominant inheritance of SPG10 is caused by two different mechanisms that both reduce the gross cargo flux, leading to deficient supply of the synapse.</p>
]]></description>
<dc:creator><![CDATA[Ebbing, B., Mann, K., Starosta, A., Jaud, J., Schols, L., Schule, R., Woehlke, G.]]></dc:creator>
<dc:date>2008-04-17</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn014</dc:identifier>
<dc:title><![CDATA[Effect of spastic paraplegia mutations in KIF5A kinesin on transport activity]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>9</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1252</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>1245</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1253?rss=1">
<title><![CDATA[Mutation of ribosomal protein RPS24 in Diamond-Blackfan anemia results in a ribosome biogenesis disorder]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/9/1253?rss=1</link>
<description><![CDATA[
<p>Diamond-Blackfan anemia (DBA) is a rare congenital disease affecting erythroid precursor differentiation. DBA is emerging as a paradigm for a new class of pathologies potentially linked to disorders in ribosome biogenesis. Three genes encoding ribosomal proteins have been associated to DBA: after <I>RPS19</I>, mutations in genes <I>RPS24</I> and <I>RPS17</I> were recently identified in a fraction of the patients. Here, we show that cells from patients carrying mutations in <I>RPS24</I> have defective pre-rRNA maturation, as in the case of <I>RPS19</I> mutations. However, in contrast to RPS19 involvement in the maturation of the internal transcribed spacer 1, RPS24 is required for processing of the 5' external transcribed spacer. Remarkably, epistasis experiments with small interfering RNAs indicate that the functions of RPS19 and RPS24 in pre-rRNA processing are connected. Resolution of the crystal structure of RPS24e from the archeon <I>Pyroccocus abyssi</I> reveals domains of RPS24 potentially involved in interactions with pre-ribosomes. Based on these data, we discuss the impact of RPS24 mutations and speculate that RPS19 and RPS24 cooperate at a particular stage of ribosome biogenesis connected to a cell cycle checkpoint, thus affecting differentiation of erythroid precursors as well as developmental processes.</p>
]]></description>
<dc:creator><![CDATA[Choesmel, V., Fribourg, S., Aguissa-Toure, A.-H., Pinaud, N., Legrand, P., Gazda, H. T., Gleizes, P.-E.]]></dc:creator>
<dc:date>2008-04-17</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn015</dc:identifier>
<dc:title><![CDATA[Mutation of ribosomal protein RPS24 in Diamond-Blackfan anemia results in a ribosome biogenesis disorder]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>9</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1263</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>1253</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1264?rss=1">
<title><![CDATA[Activation of {beta}-catenin signaling by Rspo1 controls differentiation of the mammalian ovary]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/9/1264?rss=1</link>
<description><![CDATA[
<p>The sex of an individual is determined by the fate of the gonad. While the expression of <I>Sry</I> and <I>Sox9</I> is sufficient to induce male development, we here show that female differentiation requires activation of the canonical &beta;-catenin signaling pathway. &beta;-catenin activation is controlled by Rspo1 in XX gonads and <I>Rspo1</I> knockout mice show masculinized gonads. Molecular analyses demonstrate an absence of female-specific activation of <I>Wnt4</I> and as a consequence XY-like vascularization and steroidogenesis. Moreover, germ cells of XX knockout embryos show changes in cellular adhesions and a failure to enter XX specific meiosis. Sex cords develop around birth, when <I>Sox9</I> becomes strongly activated. Thus, a balance between Sox9 and &beta;-catenin activation determines the fate of the gonad, with Rspo1 acting as a crucial regulator of canonical &beta;-catenin signaling required for female development.</p>
]]></description>
<dc:creator><![CDATA[Chassot, A.-A., Ranc, F., Gregoire, E. P., Roepers-Gajadien, H. L., Taketo, M. M., Camerino, G., de Rooij, D. G., Schedl, A., Chaboissier, M.-C.]]></dc:creator>
<dc:date>2008-04-17</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn016</dc:identifier>
<dc:title><![CDATA[Activation of {beta}-catenin signaling by Rspo1 controls differentiation of the mammalian ovary]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>9</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1277</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>1264</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1278?rss=1">
<title><![CDATA[R-spondin1 plays an essential role in ovarian development through positively regulating Wnt-4 signaling]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/9/1278?rss=1</link>
<description><![CDATA[
<p>In mammals, female development has traditionally been considered a default process in the absence of the testis-determining gene, <I>Sry</I>. Recently, it has been documented that the gene for R-spondin1 (RSPO1), a novel class of soluble activator for Wnt/&beta;-catenin signaling, is mutated in two Italian families with female-to-male (XX) sex reversal. To elucidate the role of <I>Rspo1</I> as a candidate female-determining gene in a mouse model, we generated <I>Rspo1</I>-null (<I>Rspo1</I><sup><I>&ndash;/&ndash;</I></sup>) mice and found that <I>Rspo1</I><sup><I>&ndash;/&ndash;</I></sup> XX mice displayed masculinized features including pseudohermaphroditism in genital ducts, depletion of fetal oocytes, male-specific coelomic vessel formation and ectopic testosterone production in the ovaries. Thus, although Rspo1 is required to fully suppress the male differentiation program and to maintain germ cell survival during the development of XX gonads, the loss of its activity has proved to be insufficient to cause complete XX sex reversal in mice. Interestingly, these partial sex-reversed phenotypes of <I>Rspo1</I><sup><I>&ndash;/&ndash;</I></sup> XX mice recapitulated those of previously described <I>Wnt-4</I><sup><I>&ndash;/&ndash;</I></sup> XX mice. In accordance with this finding, the expression of <I>Wnt-4</I> and its downstream genes was deregulated in early <I>Rspo1</I><sup><I>&ndash;/&ndash;</I></sup> XX gonads, suggesting that Rspo1 may participate in suppressing the male pathway in the absence of <I>Sry</I> and maintaining oocyte survival through positively regulating Wnt-4 signaling.</p>
]]></description>
<dc:creator><![CDATA[Tomizuka, K., Horikoshi, K., Kitada, R., Sugawara, Y., Iba, Y., Kojima, A., Yoshitome, A., Yamawaki, K., Amagai, M., Inoue, A., Oshima, T., Kakitani, M.]]></dc:creator>
<dc:date>2008-04-17</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn036</dc:identifier>
<dc:title><![CDATA[R-spondin1 plays an essential role in ovarian development through positively regulating Wnt-4 signaling]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>9</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1291</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>1278</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1292?rss=1">
<title><![CDATA[Targeted mRNA degradation by complex-mediated delivery of antisense RNAs to intracellular human mitochondria]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/9/1292?rss=1</link>
<description><![CDATA[
<p>Mitochondrial dysfunction underlies a large number of acute or progressive diseases, as well as aging. However, proposed therapies for mitochondrial mutations suffer from poor transformation of mitochondria with exogenous DNA, or lack of functionality of the transferred nucleic acid within the organelle. We show that a transfer RNA import complex (RIC) from the parasitic protozoon <I>Leishmania tropica</I> rapidly and efficiently delivered signal-tagged antisense (STAS) RNA or DNA to mitochondria of cultured human cells. STAS-induced specific degradation of the targeted mitochondrial mRNA, with downstream effects on respiration. These results reveal the existence of a novel small RNA-mediated mRNA degradation pathway in mammalian mitochondria, and suggest that RIC-mediated delivery could be used to target therapeutic RNAs to the organelle within intact cells.</p>
]]></description>
<dc:creator><![CDATA[Mukherjee, S., Mahata, B., Mahato, B., Adhya, S.]]></dc:creator>
<dc:date>2008-04-17</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn017</dc:identifier>
<dc:title><![CDATA[Targeted mRNA degradation by complex-mediated delivery of antisense RNAs to intracellular human mitochondria]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>9</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1298</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>1292</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1299?rss=1">
<title><![CDATA[Gene-environment interaction in progression of AMD: the CFH gene, smoking and exposure to chronic infection]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/9/1299?rss=1</link>
<description><![CDATA[
<p>A number of risk factors including the complement factor H (<I>CFH)</I> gene, smoking and <I>Chlamydia pneumoniae</I> have been associated with age-related macular degeneration (AMD). However, the mechanisms underlying how these risk factors might be involved in disease progression and disease aetiology is poorly understood. A cohort series of 233 individuals followed for AMD progression over a mean period of 7 years underwent a full eye examination, blood was taken for DNA and antibody titre and individuals completed a standard medical and general questionnaire. Y402H variants of the <I>CFH</I> gene were assessed with disease progression as well as examination of interaction between Y402H variants and smoking and Y402H variants and the pathogen <I>C</I>. <I>pneumoniae</I>. The CC risk genotype of Y402H was significantly associated with increased AMD progression [odds ratio (OR) 2.43, 95% confidence interval (95% CI) 1.07&ndash;5.49] as was smoking (OR 2.28, 95% CI 1.26&ndash;4.12). However, the risk of progression was greatly increased to almost 12-fold (OR 11.8, 95% CI 2.1&ndash;65.8) when, in addition to having the C risk allele, subjects also presented with the upper tertile of antibodies to the bacterial pathogen <I>C</I>. <I>pneumoniae</I> compared with those with the T allele of Y402H and the lowest antibody tertile. This demonstrates for the first time the existence of a gene environment&ndash;interaction between pathogenic load of <I>C</I>. <I>pneumoniae</I> and the <I>CFH</I> gene in the aetiology of AMD.</p>
]]></description>
<dc:creator><![CDATA[Baird, P. N., Robman, L. D., Richardson, A. J., Dimitrov, P. N., Tikellis, G., McCarty, C. A., Guymer, R. H.]]></dc:creator>
<dc:date>2008-04-17</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn018</dc:identifier>
<dc:title><![CDATA[Gene-environment interaction in progression of AMD: the CFH gene, smoking and exposure to chronic infection]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>9</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1305</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>1299</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1306?rss=1">
<title><![CDATA[Dnmt1 deficiency promotes CAG repeat expansion in the mouse germline]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/9/1306?rss=1</link>
<description><![CDATA[
<p>Expanded CAG repeat tracts are the cause of at least a dozen neurodegenerative disorders. In humans, long CAG repeats tend to expand during transmissions from parent to offspring, leading to an earlier age of disease onset and more severe symptoms in subsequent generations. Here, we show that the maintenance DNA methyltransferase Dnmt1, which preserves the patterns of CpG methylation, plays a key role in CAG repeat instability in human cells and in the male and female mouse germlines. SiRNA knockdown of Dnmt1 in human cells destabilized CAG triplet repeats, and Dnmt1 deficiency in mice promoted intergenerational expansion of CAG repeats at the murine spinocerebellar ataxia type 1 (<I>Sca1</I>) locus. Importantly, <I>Dnmt1</I><sup>+/&ndash;</sup> SCA1 mice, unlike their <I>Dnmt1</I><sup>+/+</sup> SCA1 counterparts, closely reproduced the intergenerational instability patterns observed in human SCA1 patients. In addition, we found aberrant DNA and histone methylation at sites within the CpG island that abuts the expanded repeat tract in Dnmt1-deficient mice. These studies suggest that local chromatin structure may play a role in triplet repeat instability. These results are consistent with normal epigenetic changes during germline development contributing to intergenerational instability of CAG repeats in mice and in humans.</p>
]]></description>
<dc:creator><![CDATA[Dion, V., Lin, Y., Hubert, L., Waterland, R. A., Wilson, J. H.]]></dc:creator>
<dc:date>2008-04-17</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn019</dc:identifier>
<dc:title><![CDATA[Dnmt1 deficiency promotes CAG repeat expansion in the mouse germline]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>9</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1317</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>1306</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1318?rss=1">
<title><![CDATA[Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/9/1318?rss=1</link>
<description><![CDATA[
<p>Platelet-activating factor acetylhydrolase (PLA2G7) is a potent pro- and anti-inflammatory molecule that has been implicated in multiple inflammatory disease processes, including cardiovascular disease. The goal of this study was to investigate the genetic effects of PLA2G7 on coronary artery disease (CAD) risk in two large, independent datasets with CAD. Using a haplotype tagging (ht) approach, 19 ht single nucleotide polymorphisms (SNPs) were genotyped in CATHGEN case&ndash;control samples (cases = 806 and controls = 267) and in the GENECARD Family Study (<I>n</I> = 1101 families, 2954 individuals). Single SNP analysis using logistic regression revealed nine SNPs with significant association in all CATHGEN subjects (<I>P</I> = 0.0004&ndash;0.02). CATHGEN cases were further stratified into subgroups based on age of CAD onset (AOO) and severity of disease; 599 young affecteds (YA, AOO &lt;56) and 207 old affected (OA, AOO &gt;56). Significant genetic effects were observed in both OA and YA (<I>P</I> = 0.0001&ndash;0.02). The GENECARD probands demonstrated results similar to those seen in the YA CATHGEN cases (<I>P</I> = 0.002&ndash;0.05). Of the 19 SNPs genotyped, 3 SNPs result in nonsynonymous coding changes (I198T, A379V and R92H). Two of the coding SNPs, R92H and A379V, constitute two of the most significantly associated SNPs, even after Bonferroni correction and appear to represent independent associations (<I>r</I><sup>2</sup> = 0.09). Multiple additional polymorphisms in low linkage disequilibrium with these coding SNPs were also strongly associated. In summary, PLA2G7 represents an important, potentially functional candidate in the pathophysiology of CAD based on replicated associations using two independent datasets and multiple statistical approaches. Further functional studies involving a combination of risk alleles are warranted.</p>
]]></description>
<dc:creator><![CDATA[Sutton, B. S., Crosslin, D. R., Shah, S. H., Nelson, S. C., Bassil, A., Hale, A. B., Haynes, C., Goldschmidt-Clermont, P. J., Vance, J. M., Seo, D., Kraus, W. E., Gregory, S. G., Hauser, E. R.]]></dc:creator>
<dc:date>2008-04-17</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn020</dc:identifier>
<dc:title><![CDATA[Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>9</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1328</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>1318</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1329?rss=1">
<title><![CDATA[A common SNP of MCPH1 is associated with cranial volume variation in Chinese population]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/9/1329?rss=1</link>
<description><![CDATA[
<p>Microcephaly (MCPH) genes are informative in understanding the genetics and evolution of human brain volume. MCPH1 and abnormal spindle-like MCPH associated (ASPM) are the two known MCPH causing genes that were suggested undergone recent positive selection in human populations. However, previous studies focusing only on the two tag single nucleotide polymorphisms(SNPs) of MCPH1 and ASPM failed to detect any correlation between gene polymorphisms and variations of brain volume and cognitive abilities. We conducted an association study on eight common SNPs of MCPH1 and ASPM in a Chinese population of 867 unrelated individuals. We demonstrate that a non-synonymous SNP (<I>rs1057090</I>, V761A in BRCA1 C-terminus (BRCT) domain) of MCPH1 other than the two known tag SNPs is significantly associated with cranial volume in Chinese males. The haplotype analysis confirmed the association of <I>rs1057090</I> with cranial volume, and the homozygote males containing the derived alleles of <I>rs1057090</I> have larger cranial volumes compared with those containing the ancestral alleles. No recent selection signal can be detected on this SNP, suggesting that the brain volume variation in human populations is likely neutral or under very weak selection in recent human history.</p>
]]></description>
<dc:creator><![CDATA[Wang, J.-k., Li, Y., Su, B.]]></dc:creator>
<dc:date>2008-04-17</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn021</dc:identifier>
<dc:title><![CDATA[A common SNP of MCPH1 is associated with cranial volume variation in Chinese population]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>9</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1335</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>1329</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/9/1336?rss=1">
<title><![CDATA[Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/9/1336?rss=1</link>
<description><![CDATA[
<p>The contribution of <I>BRCA1</I> and <I>BRCA2</I> to familial and non-familial forms of breast cancer has been difficult to accurately estimate because of the myriad of potential genetic and epigenetic mechanisms that can ultimately influence their expression and involvement in cellular activities. As one of these potential mechanisms, we investigated whether allelic imbalance (AI) of <I>BRCA1</I> or <I>BRCA2</I> expression was associated with an increased risk of developing breast cancer. By developing a quantitative approach utilizing allele-specific real-time PCR, we first evaluated AI caused by nonsense-mediated mRNA decay in patients with frameshift mutations in <I>BRCA1</I> and <I>BRCA2</I>. We next measured AI for <I>BRCA1</I> and <I>BRCA2</I> in lymphocytes from three groups: familial breast cancer patients, non-familial breast cancer patients and age-matched cancer-free females. The AI ratios of <I>BRCA1</I>, but not <I>BRCA2</I>, in the lymphocytes from familial breast cancer patients were found to be significantly increased as compared to cancer-free women (<I>BRCA1</I>: 0.424 versus 0.211, <I>P = 0.00001</I>; <I>BRCA2</I>: 0.206 versus 0.172, <I>P = 0.38</I>). Similarly, the AI ratios were greater for <I>BRCA1</I> and <I>BRCA2</I> in the lymphocytes of non-familial breast cancer cases versus controls (<I>BRCA1</I>: 0.353, <I>P</I> = 0.002; <I>BRCA2</I>: 0.267, <I>P</I> = 0.03). Furthermore, the distribution of under-expressed alleles between cancer-free controls and familial cases was significantly different for both <I>BRCA1</I> and <I>BRCA2</I> gene expression (<I>P</I> &lt; 0.02 and <I>P</I> &lt; 0.02, respectively). In conclusion, we have found that AI affecting <I>BRCA1</I> and to a lesser extent <I>BRCA2</I> may contribute to both familial and non-familial forms of breast cancer.</p>
]]></description>
<dc:creator><![CDATA[Chen, X., Weaver, J., Bove, B. A., Vanderveer, L. A., Weil, S. C., Miron, A., Daly, M. B., Godwin, A. K.]]></dc:creator>
<dc:date>2008-04-17</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn022</dc:identifier>
<dc:title><![CDATA[Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>9</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1348</prism:endingPage>
<prism:publicationDate>2008-05-01</prism:publicationDate>
<prism:startingPage>1336</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1063?rss=1">
<title><![CDATA[Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/8/1063?rss=1</link>
<description><![CDATA[
<p>Spinal muscular atrophy (SMA) is caused by loss of the survival motor neuron gene (<I>SMN1</I>) and retention of the <I>SMN2</I> gene. The copy number of <I>SMN2</I> affects the amount of SMN protein produced and the severity of the SMA phenotype. While loss of mouse <I>Smn</I> is embryonic lethal, two copies of <I>SMN2</I> prevents this embryonic lethality resulting in a mouse with severe SMA that dies 5 days after birth. Here we show that expression of full-length SMN under the prion promoter (PrP) rescues severe SMA mice. The PrP results in high levels of SMN in neurons at embryonic day 15. Mice homozygous for PrP-SMN with two copies of <I>SMN2</I> and lacking mouse <I>Smn</I> survive for an average of 210 days and lumbar motor neuron root counts in these mice were normal. Expression of SMN solely in skeletal muscle using the human skeletal actin (HSA) promoter resulted in no improvement of the SMA phenotype or extension of survival. One HSA line displaying nerve expression of SMN did affect the SMA phenotype with mice living for an average of 160 days. Thus, we conclude that expression of full-length SMN in neurons can correct the severe SMA phenotype in mice. Furthermore, a small increase of SMN in neurons has a substantial impact on survival of SMA mice while high SMN levels in mature skeletal muscle alone has no impact.</p>
]]></description>
<dc:creator><![CDATA[Gavrilina, T. O., McGovern, V. L., Workman, E., Crawford, T. O., Gogliotti, R. G., DiDonato, C. J., Monani, U. R., Morris, G. E., Burghes, A. H.M.]]></dc:creator>
<dc:date>2008-04-01</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddm379</dc:identifier>
<dc:title><![CDATA[Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1075</prism:endingPage>
<prism:publicationDate>2008-04-15</prism:publicationDate>
<prism:startingPage>1063</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1076?rss=1">
<title><![CDATA[An Actn3 knockout mouse provides mechanistic insights into the association between {alpha}-actinin-3 deficiency and human athletic performance]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/8/1076?rss=1</link>
<description><![CDATA[
<p>A common nonsense polymorphism (R577X) in the <I>ACTN3</I> gene results in complete deficiency of the fast skeletal muscle fiber protein -actinin-3 in an estimated one billion humans worldwide. The XX null genotype is under-represented in elite sprint athletes, associated with reduced muscle strength and sprint performance in non-athletes, and is over-represented in endurance athletes, suggesting that -actinin-3 deficiency increases muscle endurance at the cost of power generation. Here we report that muscle from <I>Actn3</I> knockout mice displays reduced force generation, consistent with results from human association studies. Detailed analysis of knockout mouse muscle reveals reduced fast fiber diameter, increased activity of multiple enzymes in the aerobic metabolic pathway, altered contractile properties, and enhanced recovery from fatigue, suggesting a shift in the properties of fast fibers towards those characteristic of slow fibers. These findings provide the first mechanistic explanation for the reported associations between R577X and human athletic performance and muscle function.</p>
]]></description>
<dc:creator><![CDATA[MacArthur, D. G., Seto, J. T., Chan, S., Quinlan, K. G.R., Raftery, J. M., Turner, N., Nicholson, M. D., Kee, A. J., Hardeman, E. C., Gunning, P. W., Cooney, G. J., Head, S. I., Yang, N., North, K. N.]]></dc:creator>
<dc:date>2008-04-01</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddm380</dc:identifier>
<dc:title><![CDATA[An Actn3 knockout mouse provides mechanistic insights into the association between {alpha}-actinin-3 deficiency and human athletic performance]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1086</prism:endingPage>
<prism:publicationDate>2008-04-15</prism:publicationDate>
<prism:startingPage>1076</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1087?rss=1">
<title><![CDATA[Genetic and epigenetic mechanisms combine to control MMP1 expression and its association with preterm premature rupture of membranes]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/8/1087?rss=1</link>
<description><![CDATA[
<p>Degradation of fibrillar collagens is believed to be involved in the rupture of the fetal membranes during normal parturition and when the membranes rupture prematurely. Matrix metalloproteinase 1 (MMP1) is a key enzyme involved in extracellular matrix turnover, and genetic variation in the <I>MMP1</I> promoter is associated with the risk of preterm premature rupture of membranes (PPROM). We determined whether epigenetic factors contribute to the control of MMP1 expression in the human amnion. Inhibition of DNA methylation with 5-aza-2'-deoxycytidine in amnion fibroblasts resulted in significantly increased <I>MMP1</I> gene transcription, and an associated significant increase in MMP1 production. These effects were correlated with reduced DNA methylation at a particular site (&ndash;1538) in the <I>MMP1</I> promoter. DNA methylation at this site in amnion was reduced in a larger percentage of fetal membranes that ruptured prematurely. A new T &gt; C single nucleotide polymorphism (SNP) [AF007878.1 (MMP1):g.3447T&gt;C] in the <I>MMP1</I> promoter was also identified. The minor C allele was always methylated <I>in vivo</I>, and when methylated, resulted in increased affinity for a nuclear protein in amnion fibroblasts. The minor C allele had reduced promoter activity as assessed by plasmid transfection studies and chromatin immunoprecipitation assays using amnion fibroblasts heterozygous for the T &gt; C SNP. In a case&ndash;control study, the minor C allele was found to be protective against PPROM, consistent with its reduced promoter function. We conclude that in addition to genetic variation, DNA methylation plays a role in controlling MMP1 expression and risk of an adverse obstetrical outcome.</p>
]]></description>
<dc:creator><![CDATA[Wang, H., Ogawa, M., Wood, J. R., Bartolomei, M. S., Sammel, M. D., Kusanovic, J. P., Walsh, S. W., Romero, R., Strauss, J. F.]]></dc:creator>
<dc:date>2008-04-01</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddm381</dc:identifier>
<dc:title><![CDATA[Genetic and epigenetic mechanisms combine to control MMP1 expression and its association with preterm premature rupture of membranes]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1096</prism:endingPage>
<prism:publicationDate>2008-04-15</prism:publicationDate>
<prism:startingPage>1087</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1097?rss=1">
<title><![CDATA[Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/8/1097?rss=1</link>
<description><![CDATA[
<p>Oculopharyngeal muscular dystrophy (OPMD) is a late-onset, progressive disease caused by the abnormal expansion of a polyalanine tract-encoding (GCG)<SUB>n</SUB> trinucleotide repeat in the poly-(A) binding protein nuclear 1 (<I>PABPN1</I>) gene. OPMD is generally inherited as an autosomal dominant disorder and the polyalanine expansion mutation is thought to confer a toxic gain-of-function on mutant PABPN1 which forms aggregates within skeletal myocyte nuclei. Here we describe a novel beneficial function of wild-type PABPN1. Wild-type PABPN1 over-expression can reduce mutant PABPN1 toxicity in both cell and mouse models of OPMD. In addition, wild-type PABPN1 provides some protection to cells against pro-apoptotic insults distinct from the OPMD mutation such as staurosporine treatment and Bax expression. Conversely, PABPN1 knockdown (which itself is not toxic) makes cells more susceptible to apoptotic stimuli. The protective effect of wild-type PABPN1 is mediated by its regulation of X-linked inhibitor of apoptosis (XIAP) protein translation. This normal activity of PABPN1 is partially lost for mutant PABPN1; elevated levels of XIAP are seen in mice expressing a wild-type but not a mutant PABPN1 transgene. This raises the possibility that a compromise of the anti-apoptotic function of PABPN1 might contribute to the disease mechanism of OPMD.</p>
]]></description>
<dc:creator><![CDATA[Davies, J. E., Sarkar, S., Rubinsztein, D. C.]]></dc:creator>
<dc:date>2008-04-01</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddm382</dc:identifier>
<dc:title><![CDATA[Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1108</prism:endingPage>
<prism:publicationDate>2008-04-15</prism:publicationDate>
<prism:startingPage>1097</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1109?rss=1">
<title><![CDATA[Polycystin-2 is regulated by endoplasmic reticulum-associated degradation]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/8/1109?rss=1</link>
<description><![CDATA[
<p>Endoplasmic reticulum(ER)-associated degradation (ERAD) is an essential process for cell homeostasis and remains not well understood. During ERAD, misfolded proteins are recognized, ubiquitinated on ER and subsequently retro-translocated/dislocated from ER to the 26S proteasome in the cytosol for proteolytic elimination. Polycystin-2 (PC2), a member of the transient receptor potential superfamily of cation channels, is a Ca channel mainly located on ER and primary cilium membranes of cells. Mutations in PC2 are associated with autosomal dominant polycystic kidney disease (ADPKD). The cellular and molecular mechanisms underlying the PC2-associated pathogenesis remain unclear. Here we show that PC2 degradation is regulated by the ERAD pathway through the ubiquitin&ndash;proteasome system. PC2 interacted with ATPase p97, a well-known ERAD component extracting substrates from ER, and immobilized it in perinuclear regions. PC2 also interacted with Herp, an ubiquitin-like protein implicated in regulation of ERAD. We found that Herp is required for and promotes PC2 degradation. ER stress accelerates the retro-translocation of PC2 for cytosolic degradation, at least in part through increasing the Herp expression. Thus, PC2 is a novel ERAD substrate. Herp also promoted, to varied degrees, the degradation of PC2 truncation mutants, including two pathogenic mutants R872X and E837X, as long as they interact with Herp. In contrast, Herp did not interact with, and has no effect on the degradation of, PC2 mutant missing both the N- and C-termini. The ERAD machinery may thus be important for ADPKD pathogenesis because the regulation of PC2 expression by the ERAD pathway is altered by mutations in PC2.</p>
]]></description>
<dc:creator><![CDATA[Liang, G., Li, Q., Tang, Y., Kokame, K., Kikuchi, T., Wu, G., Chen, X.-Z.]]></dc:creator>
<dc:date>2008-04-01</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddm383</dc:identifier>
<dc:title><![CDATA[Polycystin-2 is regulated by endoplasmic reticulum-associated degradation]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1119</prism:endingPage>
<prism:publicationDate>2008-04-15</prism:publicationDate>
<prism:startingPage>1109</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1120?rss=1">
<title><![CDATA[Polymorphisms in thrombospondin genes and myocardial infarction: a case-control study and a meta-analysis of available evidence]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/8/1120?rss=1</link>
<description><![CDATA[
<p>A role of thrombospondins (TSPs) in atherosclerosis and thrombosis was suggested by associations of single nucleotide polymorphisms in the genes coding for TSP-1 (rs2228262; Asn700Ser), TSP-2 (rs8089; 3' untranslated region), and TSP-4 (rs1866389; Ala387Pro) with myocardial infarction (MI). However, these findings were not consistently confirmed in replication studies. We determined the genotypes related to these polymorphisms in a large case&ndash;control sample of MI and performed a meta-analysis of data obtained in the present sample and available from prior studies that included Europeans or Americans of European origin. In the population examined here, the carriers of the minor allele of the polymorphism in the TSP-2 gene (GG and TG genotypes) had a mildly statistically significant higher risk of MI than the homozygous carriers of the major allele (TT genotype) [adjusted odds ratio (OR) 1.19; 95% confidence interval (CI), 1.02 to 1.39]. In similar comparisons, no associations of the polymorphisms in the TSP-1 (adjusted OR 1.12; 95% CI, 0.93 to 1.35) and TSP-4 (adjusted OR 0.99; 95% CI, 0.85 to 1.16) genes with MI were observed. The meta-analysis included 6388 (TSP-1), 4930 (TSP-2), and 6978 (TSP-4) cases. None of the polymorphisms was found to be linked with the risk of MI. Thus, despite associations in certain individual studies, the synthesis of available evidence did not suggest that the TSP polymorphisms included in this study were associated with MI.</p>
]]></description>
<dc:creator><![CDATA[Koch, W., Hoppmann, P., de Waha, A., Schomig, A., Kastrati, A.]]></dc:creator>
<dc:date>2008-04-01</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn001</dc:identifier>
<dc:title><![CDATA[Polymorphisms in thrombospondin genes and myocardial infarction: a case-control study and a meta-analysis of available evidence]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1126</prism:endingPage>
<prism:publicationDate>2008-04-15</prism:publicationDate>
<prism:startingPage>1120</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1127?rss=1">
<title><![CDATA[Analysis of copy number variation in the rhesus macaque genome identifies candidate loci for evolutionary and human disease studies]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/8/1127?rss=1</link>
<description><![CDATA[
<p>Copy number variants (CNVs) are heritable gains and losses of genomic DNA in normal individuals. While copy number variation is widely studied in humans, our knowledge of CNVs in other mammalian species is more limited. We have designed a custom array-based comparative genomic hybridization (aCGH) platform with 385 000 oligonucleotide probes based on the reference genome sequence of the rhesus macaque (<I>Macaca mulatta</I>), the most widely studied non-human primate in biomedical research. We used this platform to identify 123 CNVs among 10 unrelated macaque individuals, with 24% of the CNVs observed in multiple individuals. We found that segmental duplications were significantly enriched at macaque CNV loci. We also observed significant overlap between rhesus macaque and human CNVs, suggesting that certain genomic regions are prone to recurrent CNV formation and instability, even across a total of ~50 million years of primate evolution (~25 million years in each lineage). Furthermore, for eight of the CNVs that were observed in both humans and macaques, previous human studies have reported a relationship between copy number and gene expression or disease susceptibility. Therefore, the rhesus macaque offers an intriguing, non-human primate outbred model organism with which hypotheses concerning the specific functions of phenotypically relevant human CNVs can be tested.</p>
]]></description>
<dc:creator><![CDATA[Lee, A. S., Gutierrez-Arcelus, M., Perry, G. H., Vallender, E. J., Johnson, W. E., Miller, G. M., Korbel, J. O., Lee, C.]]></dc:creator>
<dc:date>2008-04-01</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn002</dc:identifier>
<dc:title><![CDATA[Analysis of copy number variation in the rhesus macaque genome identifies candidate loci for evolutionary and human disease studies]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1136</prism:endingPage>
<prism:publicationDate>2008-04-15</prism:publicationDate>
<prism:startingPage>1127</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1137?rss=1">
<title><![CDATA[Huntingtin-associated protein-1 is a modifier of the age-at-onset of Huntington's disease]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/8/1137?rss=1</link>
<description><![CDATA[
<p>A polyglutamine repeat expansion of more than 36 units in a protein called huntingtin (htt) is the only known cause of Huntington's disease (HD). The expanded repeat length is inversely correlated with the age-at-onset (AAO), however, the onset age among HD patients with CAG repeats below 60 units varies considerably. In addition to environmental factors, genetic factors different from the expanded CAG repeat length can modify the AAO of HD. We hypothezised that htt interacting proteins might contribute to this variation in the AAO and investigated human htt-associated protein-1 (HAP1) using genetic and functional assays. We identified six polymorphisms in the <I>HAP1</I> gene including one that substitutes methionine (M441) for threonine (T441) at amino acid 441. Analyzing 980 European HD patients, we found that patients homozygous for the <I>M441</I> genotype show an 8-year delay in the AAO. Functional assays demonstrated that human M441-HAP1 interacts with mutant htt more tightly than does human T441-HAP1, reduces soluble htt degraded products and protects against htt-mediated toxicity. We thus provide genetic and functional evidence that the <I>M441</I>-HAP1 polymorphism modifies the AAO of HD.</p>
]]></description>
<dc:creator><![CDATA[Metzger, S., Rong, J., Nguyen, H.-P., Cape, A., Tomiuk, J., Soehn, A. S., Propping, P., Freudenberg-Hua, Y., Freudenberg, J., Tong, L., Li, S.-H., Li, X.-J., Riess, O.]]></dc:creator>
<dc:date>2008-04-01</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn003</dc:identifier>
<dc:title><![CDATA[Huntingtin-associated protein-1 is a modifier of the age-at-onset of Huntington's disease]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1146</prism:endingPage>
<prism:publicationDate>2008-04-15</prism:publicationDate>
<prism:startingPage>1137</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1147?rss=1">
<title><![CDATA[Genetic variation in the CRP promoter: association with systemic lupus erythematosus]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/8/1147?rss=1</link>
<description><![CDATA[
<p>The pentraxin C-reactive protein (CRP), an innate immune system opsonin which binds nuclear debris and apoptotic bodies, may protect against autoimmunity. A relative deficiency of CRP levels in patients with systemic lupus erythematosus (SLE) might contribute to altered handling of self-antigens. We report that the proximal 5' promoter region of CRP contains several polymorphisms that exhibit association with SLE in multiple populations. Strongest association was observed at the proximal promoter single nucleotide polymorphism (SNP) rs3093061 (CRP-707) (<I>P</I> = 6.41 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;7</sup> and <I>P</I> = 2.13 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;6</sup> in African-American and Caucasian case&ndash;control samples respectively). This association remains after adjustment for admixture. Linkage disequilibrium exists between SNPs in the proximal promoter and association of functional haplotypes containing rs3091244/rs3093062 (CRP-409/-390) appear to be driven by the rs3093061 (CRP-707) association. These data demonstrate that rs3093061 at the -707 site within the CRP gene is an SLE susceptibility locus.</p>
]]></description>
<dc:creator><![CDATA[Edberg, J. C., Wu, J., Langefeld, C. D., Brown, E. E., Marion, M. C., McGwin, G., Petri, M., Ramsey-Goldman, R., Reveille, J. D., Frank, S. G., Kaufman, K. M., Harley, J. B., Alarcon, G. S., Kimberly, R. P.]]></dc:creator>
<dc:date>2008-04-01</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn004</dc:identifier>
<dc:title><![CDATA[Genetic variation in the CRP promoter: association with systemic lupus erythematosus]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1155</prism:endingPage>
<prism:publicationDate>2008-04-15</prism:publicationDate>
<prism:startingPage>1147</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1156?rss=1">
<title><![CDATA[Dysregulation of miRNA 181b in the temporal cortex in schizophrenia]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/8/1156?rss=1</link>
<description><![CDATA[
<p>Analysis of global microRNA (miRNA) expression in postmortem cortical grey matter from the superior temporal gyrus, revealed significant up-regulation of miR-181b expression in schizophrenia. This finding was supported by quantitative real-time RT&ndash;PCR analysis of miRNA expression in a cohort of 21 matched pairs of schizophrenia and non-psychiatric controls. The implications of this finding are substantial, as this miRNA is predicted to regulate many target genes with potential significance to the development of schizophrenia. They include the calcium sensor gene visinin-like 1 (VSNL1) and the ionotropic AMPA glutamate receptor subunit (GRIA2), which were found to be down-regulated in the same cortical tissue from the schizophrenia group. Both of these genes were also suppressed in miR-181b transfected cells and shown to contain functional miR-181b miRNA recognition elements by reporter gene assay. This study suggests altered miRNA levels could be a significant factor in the dysregulation of cortical gene expression in schizophrenia.</p>
]]></description>
<dc:creator><![CDATA[Beveridge, N. J., Tooney, P. A., Carroll, A. P., Gardiner, E., Bowden, N., Scott, R. J., Tran, N., Dedova, I., Cairns, M. J.]]></dc:creator>
<dc:date>2008-04-01</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn005</dc:identifier>
<dc:title><![CDATA[Dysregulation of miRNA 181b in the temporal cortex in schizophrenia]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1168</prism:endingPage>
<prism:publicationDate>2008-04-15</prism:publicationDate>
<prism:startingPage>1156</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1169?rss=1">
<title><![CDATA[Cis- and trans- loci influence expression of the schizophrenia susceptibility gene DTNBP1]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/8/1169?rss=1</link>
<description><![CDATA[
<p>Susceptibility to complex disease appears to be partly mediated by heritable differences in gene expression. Where <I>cis</I>-acting effects on a gene's expression influence disease susceptibility, other genes containing polymorphism with a <I>trans</I>-acting effect on expression of that gene may also be expected to modulate risk. Use of the expression of an identified disease gene as an endophenotype for quantitative linkage analysis may therefore provide a powerful method for mapping loci that modulate disease susceptibility. We performed genome-wide linkage analysis on expression of <I>dystrobrevin binding protein 1</I> (<I>DTNBP1</I>), a well-supported susceptibility gene for schizophrenia, in large CEPH pedigrees. We observed genome-wide significant evidence for linkage at the <I>DTNBP1</I> locus on chromosome 6p22, and demonstrated that this reflects variable <I>cis</I>-acting effects on <I>DTNBP1</I> expression. In addition, we observed genome-wide suggestive evidence for linkage of <I>DTNBP1</I> expression to chromosome 8p, suggesting a locus that exerts a <I>trans</I>-acting effect on <I>DTNBP1</I> expression. The region of linkage to <I>DTNBP1</I> expression on chromosome 8 is contiguous with linkage findings based upon the clinical schizophrenia phenotype, and contains another well-supported schizophrenia susceptibility gene, <I>neuregulin-1</I> (<I>NRG1</I>). Our data provide complementary evidence for chromosome 8p as a susceptibility locus for schizophrenia, and suggest that genetic variation within this region may influence risk, at least in part, through effects on <I>DTNBP1</I> expression.</p>
]]></description>
<dc:creator><![CDATA[Bray, N. J., Holmans, P. A., van den Bree, M. B., Jones, L., Elliston, L. A., Hughes, G., Richards, A. L., Williams, N. M., Craddock, N., Owen, M. J., O'Donovan, M. C.]]></dc:creator>
<dc:date>2008-04-01</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn006</dc:identifier>
<dc:title><![CDATA[Cis- and trans- loci influence expression of the schizophrenia susceptibility gene DTNBP1]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1174</prism:endingPage>
<prism:publicationDate>2008-04-15</prism:publicationDate>
<prism:startingPage>1169</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1175?rss=1">
<title><![CDATA[Atypical Mowat-Wilson patient confirms the importance of the novel association between ZFHX1B/SIP1 and NuRD corepressor complex]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/8/1175?rss=1</link>
<description><![CDATA[
<p>Mutations in <I>ZFHX1B</I> cause Mowat&ndash;Wilson syndrome (MWS) but the precise mechanisms underlying the aberrant functions of mutant ZFHX1B proteins (also named Smad-interacting protein-1, SIP1) in patients are unknown. Using mass spectrometry analysis, we identified subunits of the NuRD corepressor complex in affinity-purified Zfhx1b complexes. We find that Zfhx1b associates with NuRD through its N-terminal domain, which contains a previously postulated NuRD interacting motif. Interestingly, this motif is substituted by an unrelated sequence in a recently described MWS patient. We show here that such aberrant ZFHX1B protein is unable to recruit NuRD subunits and displays reduced transcriptional repression activity on the <I>X</I>BMP4 gene promoter, a target of Zfhx1b. We further demonstrate that the NuRD component Mi-2&beta; is involved in repression of the Zfhx1b target gene <I>E-cadherin</I> as well as in Zfhx1b-induced neural induction in animal caps from <I>Xenopus</I> embryos. Thus, NuRD and Zfhx1b functionally interact, and defective NuRD recruitment by mutant human ZFHX1B can be a MWS-causing mechanism. This is the first study providing mechanistic insight into the aberrant function of a single domain of the multi-domain protein ZFHX1B/SIP1 in human disease.</p>
]]></description>
<dc:creator><![CDATA[Verstappen, G., van Grunsven, L. A., Michiels, C., Van de Putte, T., Souopgui, J., Van Damme, J., Bellefroid, E., Vandekerckhove, J., Huylebroeck, D.]]></dc:creator>
<dc:date>2008-04-01</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn007</dc:identifier>
<dc:title><![CDATA[Atypical Mowat-Wilson patient confirms the importance of the novel association between ZFHX1B/SIP1 and NuRD corepressor complex]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1183</prism:endingPage>
<prism:publicationDate>2008-04-15</prism:publicationDate>
<prism:startingPage>1175</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1184?rss=1">
<title><![CDATA[Two different forms of palindrome resolution in the human genome: deletion or translocation]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/8/1184?rss=1</link>
<description><![CDATA[
<p>Regions containing palindromic sequence are known to be susceptible to genomic rearrangement in prokaryotes and eukaryotes. Palindromic AT-rich repeats (PATRR) are hypervariable in the human genome, manifesting size polymorphisms and a propensity to rearrange. Size variations are mainly the result of internal deletions, while two PATRRs on 11q23 and 22q11 (PATRR11 and 22) contribute to generation of the t(11;22), a recurrent constitutional translocation. In this study, we analyzed the PATRR11 sequence of numerous polymorphic alleles in detail. Various types of shorter variants are likely derived from the most frequent ~450 bp PATRR11 by deletion. Deletion variants possess a significant number of identical nucleotides at their two endpoints, indicating the possible involvement of direct repeats within the PATRR11. Rare variants with insertional alterations involve AT-rich sequences of unknown origin. This is in contrast to palindrome-mediated translocations between PATRRs that manifest smaller deletions and only a limited number of identical nucleotides at the breakpoints. Further, we identified a rare translocation product that has a non-AT-rich insertion of a transcribed gene segment at the translocation breakpoint. Our data suggest that the outcomes of palindrome-mediated re-arrangements reflect distinct molecular pathways; intra-palindrome re-arrangements are possibly dictated by a replication slippage or microhomology-directed repair pathway, and inter-palindrome translocations are likely driven by non-homologous end joining.</p>
]]></description>
<dc:creator><![CDATA[Kato, T., Inagaki, H., Kogo, H., Ohye, T., Yamada, K., Emanuel, B. S., Kurahashi, H.]]></dc:creator>
<dc:date>2008-04-01</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn008</dc:identifier>
<dc:title><![CDATA[Two different forms of palindrome resolution in the human genome: deletion or translocation]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1191</prism:endingPage>
<prism:publicationDate>2008-04-15</prism:publicationDate>
<prism:startingPage>1184</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/8/1192?rss=1">
<title><![CDATA[MeCP2-dependent repression of an imprinted miR-184 released by depolarization]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/8/1192?rss=1</link>
<description><![CDATA[
<p>Both fragile X syndrome and Rett syndrome are commonly associated with autism spectrum disorders and involve defects in synaptic plasticity. MicroRNA is implicated in synaptic plasticity because fragile X mental retardation protein was recently linked to the microRNA pathway. DNA methylation is also involved in synaptic plasticity since methyl CpG-binding protein 2 (MeCP2) is mutated in patients with Rett syndrome. Here we report that expression of miR-184, a brain-specific microRNA repressed by the binding of MeCP2 to its promoter, is upregulated by the release of MeCP2 after depolarization. The restricted release of MeCP2 from the paternal allele results in paternal allele-specific expression of miR-184. Our finding provides a clue to the link between the microRNA and DNA methylation pathways.</p>
]]></description>
<dc:creator><![CDATA[Nomura, T., Kimura, M., Horii, T., Morita, S., Soejima, H., Kudo, S., Hatada, I.]]></dc:creator>
<dc:date>2008-04-01</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn011</dc:identifier>
<dc:title><![CDATA[MeCP2-dependent repression of an imprinted miR-184 released by depolarization]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>1199</prism:endingPage>
<prism:publicationDate>2008-04-15</prism:publicationDate>
<prism:startingPage>1192</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

</rdf:RDF>